BioStock: SynAct Pharma well positioned for an eventful 2022

Biotech company SynAct Pharma finished 2021 with strong phase IIa results for AP1189 in Rheumatoid Arthritis, supporting further development within this large and commercially attractive indication. They are now preparing for a phase IIb study in RA which will incorporate the new AP1189 tablets and three month dosing. Furthermore, a listing on Nasdaq Stockholm Main Market is in the pipeline for the first half year. BioStock reached out to CEO Jeppe Øvlesen and CSO Thomas Jonassen to learn more about what is in the cards for 2022

Read the full article at biostock.se:

https://www.biostock.se/en/2022/02/synact-pharma-well-positioned-for-an-eventful-2022/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se